Xeljanz (tofacitinib) can produce noticeable improvements as early as 2 weeks, though most patients feel a meaningful difference by about 4 to 6 weeks. The exact timeline depends on the condition being treated and several individual factors, but this drug works faster than many other medications in its class. Here’s what to expect for each condition Xeljanz is prescribed for.
The First Two Weeks
Xeljanz is absorbed quickly. The immediate-release tablet reaches peak levels in your blood within about 30 minutes, and the extended-release version peaks at around 4 hours. But blood levels and symptom relief are two different things. The drug works by blocking specific signaling pathways that drive inflammation, and it takes time for that reduced inflammation to translate into less pain, stiffness, or other symptoms you can feel.
In clinical trials for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, patients on Xeljanz showed higher response rates compared to placebo at the 2-week mark, the first scheduled check-in after starting treatment. That doesn’t mean everyone feels better at 2 weeks, but it’s the earliest point where the drug starts separating from a sugar pill in measurable ways.
The immune changes that drive these improvements ramp up gradually. Reductions in certain immune cells (natural killer cells involved in inflammation) reach their maximum at roughly 8 to 10 weeks after starting therapy, which helps explain why benefits keep building well past those first couple of weeks.
Timeline for Rheumatoid Arthritis
For RA, the standard dose is 5 mg twice daily (or 11 mg once daily for the extended-release version). Most patients notice improvement in symptoms by one month, according to Johns Hopkins Arthritis Center. The first signs are typically less morning stiffness and reduced joint tenderness. Swelling tends to follow, improving more gradually over the next several weeks.
Clinical trials measured response using a standardized scale that tracks tender and swollen joint counts, pain levels, and physical function. Statistically significant improvements appeared at week 2, but the response continued to build through months 3 and 6. If you’ve been on Xeljanz for 3 months without meaningful improvement, that’s generally the point where your rheumatologist will reassess whether the drug is working for you.
Timeline for Ulcerative Colitis
Xeljanz can work surprisingly fast for ulcerative colitis. A real-world study published in Inflammatory Bowel Diseases tracked patients from day 3 onward and found significant improvements in rectal bleeding, stool frequency, and urgency within just 3 days of starting treatment. By day 3, 29% of patients with rectal bleeding saw a meaningful decrease, and 23% reported less urgency.
By day 14, the numbers were more striking: 47% of patients were in remission based on symptom scores, and 65% had a clinical response. More than half of patients had no rectal bleeding at all by that point, and 59% reported normal stool frequency. These gains held steady or continued improving through day 56.
The dosing schedule for UC reflects this timeline. You start on a higher induction dose (10 mg twice daily or 22 mg once daily) for 8 weeks. If you’re responding, your doctor will step you down to a lower maintenance dose. If not, the higher dose can continue for up to 16 weeks total before it’s considered a treatment failure.
Timeline for Psoriatic Arthritis and Ankylosing Spondylitis
For psoriatic arthritis, clinical trials showed measurable improvement in joint symptoms at the first post-baseline visit, which was week 2. The pattern is similar to RA: early gains in pain and stiffness, with continued improvement over the following months.
For ankylosing spondylitis, a phase III trial found a rapid onset of response as early as week 2, with significant differences from placebo in back pain, morning stiffness, and physical function. Stronger responses (meeting higher thresholds of improvement) became significant by week 4 and continued through week 16.
What Affects How Fast It Works
Not everyone responds on the same schedule, and a few factors help explain why. The most important predictor is how active your disease is when you start. For ulcerative colitis, patients with lower baseline disease activity were significantly more likely to achieve remission during the induction period. Those with the most severe disease scores had roughly half the remission rate of those with moderate disease.
Prior treatment history also matters. Patients who had previously tried and failed a TNF inhibitor (a different class of biologic) were less likely to achieve mucosal healing in UC, suggesting the drug may work somewhat slower or less completely in treatment-experienced patients. Standard demographics like age, sex, body weight, and smoking status were also evaluated, but baseline disease severity was consistently the strongest factor influencing response speed.
Inflammation markers in your blood, particularly C-reactive protein levels, also predicted how quickly patients responded. Higher inflammation at the start was associated with a different response trajectory, which is why your doctor may check bloodwork before and after starting treatment.
Signs the Drug Is Working
The earliest improvements you’re likely to notice depend on your condition. For inflammatory arthritis (RA, PsA, or AS), look for less morning stiffness and reduced joint tenderness. These tend to improve before visible swelling goes down. You may also notice that you can do more during the day without pain, or that your energy improves as systemic inflammation decreases.
For ulcerative colitis, the first signs are often reduced urgency and less blood in your stool. Stool frequency tends to normalize next. Because these symptoms can fluctuate day to day, tracking them over a full week gives you a clearer picture than comparing any single day to the one before it.
If you’re 8 weeks in with no noticeable change, that’s a reasonable window to discuss next steps. For UC specifically, the prescribing information sets a hard boundary: if 16 weeks on the higher induction dose hasn’t produced an adequate response, the drug should be discontinued. For RA and related conditions, the evaluation window is less rigid, but 3 months without improvement is a common reassessment point.